Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Rises By 22.6%

Vincerx Pharma, Inc. (NASDAQ:VINC) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 735,400 shares, an increase of 22.6% from the November 15th total of 600,000 shares. Based on an average daily trading volume, of 607,900 shares, the days-to-cover ratio is currently 1.2 days.

Vincerx Pharma Stock Down 2.5 %

Shares of NASDAQ VINC traded down $0.00 during trading on Monday, hitting $0.19. The company had a trading volume of 256,615 shares, compared to its average volume of 674,744. The stock has a fifty day simple moving average of $0.32 and a two-hundred day simple moving average of $0.56. Vincerx Pharma has a fifty-two week low of $0.18 and a fifty-two week high of $9.37. The firm has a market capitalization of $6.27 million, a price-to-earnings ratio of -0.19 and a beta of 1.48.

Hedge Funds Weigh In On Vincerx Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the business. Armistice Capital LLC purchased a new position in shares of Vincerx Pharma in the second quarter worth about $1,610,000. Marshall Wace LLP lifted its stake in shares of Vincerx Pharma by 359.1% in the second quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock worth $266,000 after buying an additional 256,967 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Vincerx Pharma by 29.9% in the first quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock worth $3,375,000 after buying an additional 153,575 shares in the last quarter. 44.02% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Leerink Partners dropped their price target on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.